GSK vs TRNS · P/E 13, $103.31B cap vs P/E 57, rev $92.9M
GlaxoSmithKline PLC ADR (GSK) versus Transcat Inc (TRNS) — a side-by-side from cached financials, not a winner call.
GlaxoSmithKline PLC ADR (GSK) is a drug manufacturers - general company listed on US.
Transcat Inc (TRNS) is a specialty business services company listed on US.
GSK does not have a complete income-statement cache yet.
Latest reported TRNS revenue for 2026-06-27 was $92.9M. Net income was $1.3M. Revenue was down 61.7% from 2025-12-27 to 2026-06-27. TRNS currently screens at market cap $837.5M and trailing P/E 57.2.
GSK currently screens at market cap $103.31B and trailing P/E 13.5. TRNS currently screens at market cap $837.5M and trailing P/E 57.2.
Not investment advice. Open the GSK and TRNS stock pages for the full models.
Not investment advice.